CION Ameerpet
Prognosis & Recurrence · Reviewed by CION Oncologists · NABH Accredited
What Affects Endometrial Cancer Prognosis
If you have a pathology report in front of you, you have probably fixed on one line — and it is almost certainly the most frightening one. Prognosis in endometrial cancer is not read off any single factor. It emerges from a combination: stage, type, grade, depth of invasion, lymphovascular invasion, node status and molecular class, weighed together. Reading one in isolation gives a distorted picture, and in practice it distorts towards the worse. This page explains what each factor contributes, why molecular class can move the assessment in either direction, and how to read survival statistics without being misled by them.
- Stage matters most — and most cases are found early
- It is a combination — no single line is your prognosis
- Molecular class cuts both ways — better as well as worse
- Statistics describe groups — they do not predict individuals
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Factors, and What Each Contributes
Roughly in order of how much weight each carries. They interact, which is why the combination matters more than any row on its own.
| Factor | What it contributes |
|---|---|
| Stage | The strongest single determinant — how far the disease has spread. Most endometrial cancers are found confined to the uterus, which is the most favourable situation, and this is the direct benefit of the disease announcing itself through bleeding. See FIGO staging. |
| Histological type | Endometrioid carcinoma, the commonest, is generally the most favourable. Serous, clear cell and carcinosarcoma behave more aggressively regardless of other features. See uterine cancer types. |
| Molecular class | Now part of staging itself. POLE-ultramutated is the most favourable of the four groups; p53-abnormal the least. It can override the impression grade gives, in either direction. See molecular classification. |
| Grade | How closely the tumour resembles normal lining. Grade 1 is most favourable, grade 3 least. Important, and less decisive than it used to be now that molecular class is available. See grades explained. |
| Depth of invasion | How far into the muscle wall the tumour has grown. Less than half its thickness is a materially better position than more than half, and it is one of the strongest predictors of whether treatment after surgery is recommended. |
| Lymphovascular space invasion | Tumour cells inside small vessels near the tumour. Substantial LVSI raises the risk of node involvement and recurrence; focal LVSI carries considerably less weight. Ask which yours says. See your pathology report. |
| Lymph node status | Whether nodes contain cancer. Involvement means stage III — which is still treated with curative intent, a point worth hearing plainly. See lymph nodes. |
| Complete removal, and your general health | Whether all visible disease was removed matters, particularly in advanced disease. So does your overall fitness, because it determines what treatment you can be given and how well you tolerate it. |
These interact rather than adding up. A grade 3 tumour confined to the lining, completely removed and POLE-mutated is a very different situation from grade 3 with deep invasion and involved nodes. If a single line on your report has frightened you, the honest response is to ask what the whole combination means — and the answer is usually better than the line alone suggested.
Did You Know? Molecular classification did something unusual when it entered practice: it made prognosis more accurate in both directions, not just more pessimistic. A grade 3 tumour that looks alarming under the microscope but carries a POLE mutation behaves considerably better than its appearance suggests, and women in that group can safely be spared treatment their grade alone would have prompted. A tumour that looks low risk but shows abnormal p53 behaves worse than the conventional factors indicate, and warrants more. Before this was available, both women were treated according to how the cells looked. That is why molecular class now sits inside FIGO 2023 staging rather than alongside it. Sources: FIGO 2023 staging system for endometrial cancer; The Cancer Genome Atlas Research Network, integrated genomic characterization of endometrial carcinoma; ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
How to Read Survival Statistics
Five things that make published figures much less frightening and much more useful.
- They describe groups, not people. A five-year survival figure tells you what proportion of a large group of women was alive at five years. It tells you nothing about which side of that figure any individual falls on, and it is not a prediction about you.
- They are historical by construction. Five-year data necessarily describes women diagnosed at least five years ago, and usually longer. Improvements in surgery, radiotherapy delivery, molecular characterisation and systemic treatment since then are not reflected.
- They average across everyone. Every age, every level of general health, every treatment and none. A woman who is fit and had complete surgery is not the average of that group.
- Stage-specific figures are more useful than overall ones. And figures that also account for type and molecular class are more useful still. Overall survival for “endometrial cancer” averages across situations that have almost nothing in common. See survival by stage.
- Indian data is limited. Most published figures come from registries elsewhere, principally in the United States and Europe. That is a genuine limitation and it is a reason to treat any single number with caution rather than a reason to assume the worst.
Want the Whole Combination Explained?
Not one line in isolation. Every factor gone through, with molecular testing completed if it is missing.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
No Single Line Is Your Prognosis
The factors interact. Read alone, the scariest line is almost always misleading.
What Is Within Your Influence
Most prognostic factors were determined before you knew you had cancer. These are not.
Getting the molecular classification done
The clearest one. It is part of current staging, it can reduce as well as increase the treatment recommended, and it is sometimes omitted. If your report says nothing about mismatch repair or p53, ask — it can nearly always be done on the stored tissue block. See MMR and MSI testing.
Where you have surgery
Completeness of surgical removal matters, particularly in higher-stage disease, and node assessment technique determines your lymphoedema risk for the rest of your life. Both depend on the team. See choosing a centre.
Whether a full board reviewed your case
The recommendation about treatment after surgery weighs surgical, radiotherapy and systemic considerations together. A plan assembled by one specialty tends to reflect that specialty's tools. Ask whether your case was discussed and what was concluded.
Completing the treatment recommended
Unglamorous and it matters. Finishing a course of radiotherapy or chemotherapy as planned, and attending follow-up, both affect outcome — and both are where practical obstacles quietly derail things. Say what the obstacle is rather than dropping out.
Reporting symptoms promptly afterwards
Most recurrences are found because a woman reported something, not by routine scans. Vault recurrence in particular is frequently curable when caught early. See detecting recurrence.
Want Someone to Go Through It With You?
Bring your pathology report. Every factor explained, and what the combination actually means. The opinion is free.
Keeping This in Proportion
Five things that are accurate and worth holding on to.
- Most endometrial cancer is found early. Because it bleeds, and bleeding after menopause sends women to a doctor. The majority of cases are confined to the uterus at diagnosis, where outcomes are good.
- Early-stage disease is frequently cured by surgery alone. Many women need no further treatment at all, and that is a genuinely common outcome rather than a best case.
- Molecular classification has improved accuracy in both directions. A meaningful number of women are now spared treatment they would previously have received, on the strength of a favourable molecular result.
- Even node-positive disease is treated to cure. Stage III endometrial cancer is treated with curative intent, and hearing that said plainly matters. See stage 3.
- Searching statistics at night is punishing and misleading. Almost every figure you find will be an old average across situations unlike yours. Write the question down and ask it in daylight, of someone who has your report. See coping with a diagnosis.
Why the Combination Needs a Consultation
Six or seven factors interacting is not something a page can resolve for you. It is what an appointment is for.
45-minute consultations
MMR / MSI testing as standard
Tumour board for every diagnosis
Slides reviewed, not just the summary line
Costs explained before you commit
Second opinions welcomed, not resented
Take The Next Step
Ask What the Whole Picture Means
Not what the one line means. The answer is usually better than the line alone suggested.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Prognosis Factors — Frequently Asked Questions
What is the most important factor in endometrial cancer prognosis?
Stage — how far the disease has spread — is the strongest single determinant, and this is genuinely encouraging for most women, because the majority of endometrial cancers are found while still confined to the uterus. That is the direct benefit of the disease announcing itself through abnormal bleeding. After stage come histological type, molecular class, grade, depth of invasion into the muscle wall, lymphovascular space invasion and lymph node status. They interact rather than adding up, which is why any single factor read in isolation gives a distorted impression — usually a worse one than the whole picture supports.
My report says grade 3. Does that mean a poor outcome?
Not on its own, and grade has become less decisive than it used to be. A grade 3 tumour confined to the lining, completely removed and shown to be POLE-ultramutated has an excellent outlook — that molecular group behaves far better than its microscopic appearance suggests, and appropriately selected women may need less treatment rather than more. A grade 3 tumour with deep invasion and involved lymph nodes is a different situation entirely. This is precisely why molecular classification matters, and why it is worth asking for if your report does not mention it.
How much can I rely on survival statistics I find online?
Treat them as background rather than as information about you. Published figures describe groups of women diagnosed at least five years ago and usually longer, averaged across every age, every level of general health and every treatment. They cannot predict an individual outcome, and they lag behind current practice — improvements in surgery, radiotherapy, molecular characterisation and systemic treatment since the data were collected are not reflected. Stage-specific figures are more useful than overall ones, and figures accounting for type and molecular class more useful still. Indian registry data on this disease is also limited.
Can anything I do change my prognosis?
Several things, and they are worth knowing because most prognostic factors were set before you knew you had cancer. Ensure molecular classification is done — it is part of current staging, it can reduce as well as increase the treatment recommended, and it is sometimes omitted. Have surgery at a centre that performs comprehensive staging and sentinel node mapping. Ask whether a full multidisciplinary board reviewed your case. Complete the treatment recommended rather than dropping out when practical obstacles arise. And report symptoms promptly afterwards, since most recurrences are found that way.
Why does molecular classification matter so much now?
Because it made prognostic assessment more accurate in both directions rather than only identifying worse cases. A POLE-ultramutated tumour behaves considerably better than its grade suggests, and women in that group can safely avoid radiotherapy or chemotherapy their grade alone would have prompted. A p53-abnormal tumour behaves worse than conventional factors indicate and warrants intensification. Before molecular testing, both were treated according to how the cells looked under a microscope. It is now incorporated into FIGO 2023 staging, which means a tumour that has not been classified has not been fully staged.
Medical disclaimer: This page provides general information about factors affecting prognosis in endometrial cancer, reviewed by a CION oncologist. It is not a substitute for individual medical advice. Published survival statistics describe groups of patients treated in the past and cannot predict outcome for any individual. Your prognosis should be discussed with your treating team in the context of your complete pathology and clinical circumstances.